[go: up one dir, main page]

MX2010001416A - Compuesto para el tratamiento de la hepatitis c. - Google Patents

Compuesto para el tratamiento de la hepatitis c.

Info

Publication number
MX2010001416A
MX2010001416A MX2010001416A MX2010001416A MX2010001416A MX 2010001416 A MX2010001416 A MX 2010001416A MX 2010001416 A MX2010001416 A MX 2010001416A MX 2010001416 A MX2010001416 A MX 2010001416A MX 2010001416 A MX2010001416 A MX 2010001416A
Authority
MX
Mexico
Prior art keywords
compounds
hepatitis
treatment
hcv
virus
Prior art date
Application number
MX2010001416A
Other languages
English (en)
Inventor
Carl P Bergstrom
Scott W Martin
Robert G Gentles
Kap-Sun Yeung
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2010001416A publication Critical patent/MX2010001416A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención incluye compuestos de fórmula I así como composiciones y procedimientos de uso de los compuestos. Los compuestos tienen actividad contra el virus de la hepatitis c (VHC) y son útiles en el tratamiento de sujetos infectados por el VHC.
MX2010001416A 2007-08-09 2008-08-01 Compuesto para el tratamiento de la hepatitis c. MX2010001416A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95481407P 2007-08-09 2007-08-09
US4994408P 2008-05-02 2008-05-02
US12/180,994 US7652004B2 (en) 2007-08-09 2008-07-28 Compounds for the treatment of hepatitis C
PCT/US2008/071881 WO2009029384A2 (en) 2007-08-09 2008-08-01 Compounds for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
MX2010001416A true MX2010001416A (es) 2010-03-01

Family

ID=40261456

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001416A MX2010001416A (es) 2007-08-09 2008-08-01 Compuesto para el tratamiento de la hepatitis c.

Country Status (18)

Country Link
US (1) US7652004B2 (es)
EP (1) EP2183252B1 (es)
JP (1) JP5465670B2 (es)
KR (1) KR20100066492A (es)
CN (1) CN101821267B (es)
AR (1) AR067897A1 (es)
AU (1) AU2008293845B2 (es)
BR (1) BRPI0814931A2 (es)
CA (1) CA2695781A1 (es)
CL (1) CL2008002353A1 (es)
CO (1) CO6251359A2 (es)
EA (1) EA015978B1 (es)
MX (1) MX2010001416A (es)
NZ (1) NZ583149A (es)
PE (1) PE20090618A1 (es)
TW (1) TW200906418A (es)
WO (1) WO2009029384A2 (es)
ZA (1) ZA201000923B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005049622A1 (ja) * 2003-11-19 2007-06-07 日本たばこ産業株式会社 ５−５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
PT2209789E (pt) * 2007-11-20 2012-01-16 Bristol Myers Squibb Co Inibidores de ns5b de vhc de indolbenzazepina condensados com ciclopropilo
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
ATE531373T1 (de) 2008-03-27 2011-11-15 Bristol Myers Squibb Co Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP2012517468A (ja) * 2009-02-11 2012-08-02 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎治療のための化合物
JP5918264B2 (ja) 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Ｃ型肝炎阻害剤およびその使用
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
CN103635461B (zh) * 2011-06-22 2016-01-20 中央硝子株式会社 吡唑化合物的制造方法
WO2014014885A1 (en) * 2012-07-18 2014-01-23 Bristol-Myers Squibb Company Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
PE20060607A1 (es) 2004-10-26 2006-07-14 Angeletti P Ist Richerche Bio Derivados de indol tetraciclicos como agentes antivirales
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2343914T3 (es) * 2006-05-25 2010-08-12 Bristol-Myers Squibb Company Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo.
US7521442B2 (en) * 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
AU2008293845A1 (en) 2009-03-05
WO2009029384A3 (en) 2009-05-28
JP2010535787A (ja) 2010-11-25
US20090074715A1 (en) 2009-03-19
CL2008002353A1 (es) 2008-10-24
CN101821267A (zh) 2010-09-01
US7652004B2 (en) 2010-01-26
TW200906418A (en) 2009-02-16
EA015978B1 (ru) 2012-01-30
EP2183252A2 (en) 2010-05-12
JP5465670B2 (ja) 2014-04-09
ZA201000923B (en) 2011-04-28
CA2695781A1 (en) 2009-03-05
WO2009029384A2 (en) 2009-03-05
KR20100066492A (ko) 2010-06-17
AU2008293845B2 (en) 2013-02-14
EP2183252B1 (en) 2015-01-14
BRPI0814931A2 (pt) 2015-02-03
CN101821267B (zh) 2013-07-10
CO6251359A2 (es) 2011-02-21
NZ583149A (en) 2011-07-29
AR067897A1 (es) 2009-10-28
EA201000277A1 (ru) 2010-06-30
PE20090618A1 (es) 2009-05-16

Similar Documents

Publication Publication Date Title
PL1987038T3 (pl) Inhibitory HCV NS5B
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
ATE469155T1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
MX2010005226A (es) Inhibidores de ns5b de hcv de indolobenzazepina fusionados a ciclopropilo.
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2010030538A3 (en) Compounds for the treatment of hepatitis c
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
EA200900298A1 (ru) Ингибиторы вируса гепатита с
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
MX2010008749A (es) Inhibidores del virus de la hepatitis c.
EA201001275A1 (ru) Конформационно-ограниченные бифенильные производные для применения в качестве ингибиторов вируса гепатита с
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
EA201270656A1 (ru) Ингибиторы вируса гепатита с
ATE551337T1 (de) Inhibitoren des hepatitis-c-virus
EA201101082A1 (ru) Ингибиторы вируса гепатита с
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
MX2010010061A (es) Compuestos para el tratamiento de hepatitis c.
MX2010010235A (es) Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.

Legal Events

Date Code Title Description
FG Grant or registration